MET and non-small cell lung carcinoma: In contrast to this, a phase II study by Spigel et al. performed on NSCLC patients found that both median PFS and OS were significantly longer in a MET positive subgroup (defined as MET IHC3+ or IHC2+) treated with onartuzumab and erlotinib compared to a subgroup treated with erlotinib and placebo (dual treatment PFS = 2.9 months, OS = 12.6 months; single treatment PFS = 1.5 months, OS = 3.8 months).